CD19 CAR Construct with CD28 Costimulation for T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies for cancer treatment face limitations in prolonged expansion and anti-tumor activity due to suboptimal activation of first-generation CARs, necessitating the development of more effective chimeric antigen receptors that can specifically target CD19-expressing tumor cells.
Innovation Solution
A CD19-directed chimeric antigen receptor (CAR) construct is developed, comprising a single-chain antibody with a light chain variable domain and a heavy chain variable domain that are at least 95% homologous to specific sequences, along with a transmembrane domain and intracellular signaling domains, including CD28 and CD3ζ, to enhance T-cell cytotoxicity against CD19-expressing tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation CARs are used to redirect T cell cytotoxicity, then T cells can specifically bind target antigens, but prolonged expansion and anti-tumor activity are not achieved
Solution Approach 1:
The patent combines multiple signaling domains (CD3ζ for activation signal and CD28 for costimulation signal) into a single chimeric antigen receptor construct. This merging of signaling functions within one CAR molecule enables both initial T cell activation and sustained proliferation, resolving the contradiction between achieving reliable anti-tumor activity and maintaining prolonged expansion of CAR-T cells.
2Adaptability or versatility
If T cells are engineered with CAR genes to provide MHC-unrestricted killing, then general therapy for all patients bearing the same antigen is achieved, but suboptimal activation limits anti-tumor efficacy
Solution Approach 1:
The patent creates a composite signaling structure by integrating the CD3ζ signaling domain (providing MHC-unrestricted antigen recognition and activation) with the CD28 signaling domain (providing costimulatory signals for enhanced activation and survival). This composite CAR construct maintains the versatility of MHC-unrestricted killing while improving reliability of anti-tumor efficacy through dual signaling pathways.
Data Source
AI summary
Disclosed in the present application are CAR constructs that encode domains of anti-CD19 antibodies, T cells that include and express the CD19 CAR constructs, and methods of use, such as methods of treating disease, including hematological cancers, using CAR-T cells that express the CD19 CAR constructs.